Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Is SNY or BMY a better dividend stock?

Sanofi pays an annual dividend of $1.48 per share and has a dividend yield of 3.1%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 4.1%. Sanofi pays out 75.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol-Myers Squibb pays out -66.9% of its earnings in the form of a dividend. Bristol-Myers Squibb has increased its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has preferable earnings & valuation, SNY or BMY?

Bristol-Myers Squibb has higher revenue and earnings than Sanofi. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$46.61B	2.60	$5.84B	$1.96	24.38
Bristol-Myers Squibb	$47.44B	2.47	$8.03B	-$3.59	-16.12

Do analysts recommend SNY or BMY?

Sanofi currently has a consensus target price of $57.50, indicating a potential upside of 20.34%. Bristol-Myers Squibb has a consensus target price of $54.07, indicating a potential downside of 6.58%. Given Sanofi's stronger consensus rating and higher possible upside, equities analysts plainly believe Sanofi is more favorable than Bristol-Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Bristol-Myers Squibb	2 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.20

Does the media favor SNY or BMY?

In the previous week, Bristol-Myers Squibb had 61 more articles in the media than Sanofi. MarketBeat recorded 82 mentions for Bristol-Myers Squibb and 21 mentions for Sanofi. Bristol-Myers Squibb's average media sentiment score of 0.91 beat Sanofi's score of 0.89 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol-Myers Squibb	46 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, SNY or BMY?

Sanofi has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of SNY or BMY?

10.0% of Sanofi shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in SNY or BMY?

Bristol-Myers Squibb received 1037 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 66.22% of users gave Bristol-Myers Squibb an outperform vote while only 62.82% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 49 62.82%	Underperform Votes 29 37.18%
Bristol-Myers Squibb	Outperform Votes 1086 66.22%	Underperform Votes 554 33.78%

Is SNY or BMY more profitable?

Sanofi has a net margin of 9.96% compared to Bristol-Myers Squibb's net margin of -15.30%. Sanofi's return on equity of 27.45% beat Bristol-Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	9.96%	27.45%	15.79%
Bristol-Myers Squibb	-15.30%	11.94%	2.51%

Summary

Bristol-Myers Squibb beats Sanofi on 12 of the 22 factors compared between the two stocks.